File S1 - Transcriptional Regulation of the Tumor Suppressor FHL2 by p53 in Human Kidney and Liver Cells

Table S1. Clinical features of HCC patients. The patients were categorized according to their sex, age, tumour size, differentiation status, tumour stage, HBV infection and cirrhosis and fibrosis status. *The total number is less than 41 because of some missing data. Figure S1. Bioinformatic prediction of p53 binding sites in FHL2 (A) 1a promoter (position −2139 to +375) and (B) 1b promoter (position −2268 to +397). Four computational programs were used to predict the p53 binding sites: MatInspector, JASPAR, PROMO and PATCH, representing in red, blue, green, and purple rectangles respectively. The conserved regions among different species are highlighted in blue.
(DOCX)